Article

Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL

2023-06-10

Abstract excerpt

<h4>ABSTRACT</h4> <h4>PURPOSE</h4> 60-70% of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients avoid events within 24 months of diagnosis (EFS24) and the remainder have poor outcomes. Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide anticipatory selection of novel therapies. To address this unmet...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fe456a61-d02b-59de-a731-e1319fc5562d
DOI: 10.1101/2023.06.07.23290748

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCLDOI 10.1101/2023.06.07.23290748Read

Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL.Semantic proximity Read

Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosisSemantic proximity Read

Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.Semantic proximity Read

Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes.Semantic proximity Read

Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signatureSemantic proximity Read

Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphomaSemantic proximity Read

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphomaSemantic proximity Read

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulationSemantic proximity Read

Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.Semantic proximity Read

Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell LymphomaSemantic proximity Read

A single-cell atlas of diffuse large B cell lymphomaSemantic proximity Read